RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (Australia), Priority Review (United States), Conditional marketing approval (China), Priority Review (China), Breakthrough Therapy (United States)

Structure/Sequence

Molecular FormulaC28H22ClF3N6O3

InChIKeyWIJZXSAJMHAVGX-DHLKQENFSA-N

CAS Registry1448347-49-6

Clinical Trials associated with Ivosidenib

NCT07006688

/ Not yet recruitingPhase 1

A Phase 1, Multicenter, Open-Label, Safety and Pharmacokinetic Study of Orally Administered Ivosidenib in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

The objective of this study is to investigate the PK, PD, safety, and tolerability of ivosidenib in adult participants with IDH1-mutated malignancies and hepatic impairment (HI)/ renal impairment (RI). Participants will be enrolled into one of 5 groups based on their hepatic or renal function. During the treatment period participants will have study visits on days 1, 4, 8, 15, 22, and 28 of Cycle 1, on days 1 and 15 of Cycle 2 and 3, and on day 1 of each additional cycle. Each cycle is 28 consecutive days of treatment and cycles will be continuous until the end of the study. Approximately 30 days after treatment has ended, a safety follow-up visit will occur. Study visits may include blood tests, ECG, vital signs, and a physical examination.

Start Date01 Jan 2026

Sponsor / Collaborator

Servier Bio-Innovation LLC

[+1]

NCT06707493

/ RecruitingPhase 2IIT

A Randomized, Placebo-Controlled Phase 2 Study of IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).

Start Date08 Dec 2025

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT07260175

/ RecruitingPhase 2IIT

adIVO - A Phase II Trial of Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

This study trial is a prospective, multicentre, exploratory, single-arm, open-label phase II study to evaluat ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

Start Date18 Nov 2025

Sponsor / Collaborator

Servier Deutschland GmbH

[+1]

100 Clinical Results associated with Ivosidenib

100 Translational Medicine associated with Ivosidenib

100 Patents (Medical) associated with Ivosidenib

352

Literatures (Medical) associated with Ivosidenib

19 Jan 2026·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies

Review

Author: Nucci, Marcio ; Maertens, Johan

Abstract:

The therapeutic landscape of acute leukaemia (AL) has evolved profoundly with the introduction of targeted and differentiation agents, altering the epidemiology of invasive fungal disease (IFD). While antifungal prophylaxis with triazoles remains standard for patients receiving intensive chemotherapy, this paradigm may no longer apply to those treated with novel regimens. Targeted agents such as tyrosine kinase inhibitors, blinatumomab, inotuzumab ozogamycin, ivosidenib, gilteritinib, and venetoclax are associated with higher remission rates, shorter or absent neutropenia, and minimal mucosal injury—key determinants of IFD risk. As a result, the incidence of IFD appears markedly lower in such populations. Redefining antifungal prophylactic strategies must account for this therapeutic heterogeneity to avoid overexposure to antifungal drugs and misdirected research priorities. Updated, risk-adapted strategies—integrating treatment intensity, myelotoxicity, and drug interactions—are essential to define which AL patients truly benefit from primary antifungal prophylaxis in the modern era.

01 Jan 2026·Hepatobiliary & Pancreatic Diseases International

Cost-effectiveness of ivosidenib in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma: An Italian perspective

Letter

Author: Sava, Teodoro ; Giuliani, Jacopo ; Fiorica, Francesco ; Muraro, Marco ; Durante, Emilia ; Muraro, Silvia ; Tommasi, Marina

08 Dec 2025·Future Oncology

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML

Article

Author: Vives, Susana ; Pelouchova, Jana ; Vyas, Paresh ; Venditti, Adriano ; Döhner, Hartmut ; Salek, Sam ; Recher, Christian ; Hills, Ralph ; De La Bigne, Anne-Marie ; Nier, Samantha ; Chatin, Stéphanie ; Derrien, Hélène

AIMS:

The ALIDHE study aims to supplement previous clinical trial data by evaluating the safety and tolerability of ivosidenib + azacitidine in adult patients with newly diagnosed mutant isocitrate dehydrogenase acute myeloid leukemia (AML).

METHODS:

Notably, this study has been designed in collaboration with patient representatives from the Acute Leukemia Advocates Network (ALAN) at all stages. Patient representatives from ALAN completed a survey and attended workshops to share feedback on the study design to reduce the burden of participation for patients. Using feedback from ALAN, the study protocol was adjusted to minimize clinical visits and optimize study duration. Quality of life and mental health were included as endpoints in ALIDHE as these outcomes have been recognized as important to capture the lived experiences of patients with AML. Efforts were made to ensure patient comprehension through accessible study documents such as a plain language video and one-page summary.

CONCLUSIONS:

ALIDHE represents, to our knowledge, the first AML clinical trial that involves patient representatives from development of the study concept to follow-up. ALAN will continue to be involved in ALIDHE as part of the patient steering committee, to ensure that patient perspectives and needs continue to be considered throughout the study duration.

128

News (Medical) associated with Ivosidenib

27 Jan 2026

·www.prnewswire.com

Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. Growth over the financial year was driven by increased sales in oncology, particularly in the United States. Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases. Achieving 2025 targets reflects successful transformation that began in 2015 and underpins the Group's ambitions for 2030. SURESNES, France, Jan. 27, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, published its financial results for the 2024/25 financial year today and recapped the highlights that led to such significant growth. Olivier Laureau, President of Servier, said: "The solid results from our 2024/25 financial year put us one important step closer to achieving our 2030 objectives. They validate the relevance of our differentiated innovation strategy to serve patients and the commitment of our employees. These results also underscore the success of the Group's transformation, which began 10 years ago, involving significant investments in innovation and international expansion. Our long-term vision is made possible by the fact that we are governed by a foundation." Excerpt from the Group's audited results [1] (financial year ending September 30, 2025) In the 2024/25 financial year, Group revenue reached €6.9 billion, exceeding the €6 billion target. This 16.2% increase over the previous year reflects the Group's growth momentum and ability to provide patients with an ever-increasing number of medicines. Revenue growth resulted from a 16.9% increase in sales volume, or €1 billion, compared to 12.6% for FY 2023/24. There was also an unfavorable currency effect of 2.0%, equivalent to €118 million, (compared with an unfavorable impact of 3.5% in the previous year), as well as a positive price effect of 1.3%, equal to €76 million (compared with 1.7% for the 2023/24 financial year). EBITDA[2] for the 2024/25 financial year amounted to €1.9 billion, corresponding to a 28.2% revenue margin compared to 22.2% in 2023/24. This increase was driven by significant growth in medicine sales during the financial year, particularly in oncology, combined with effective cost control across the Group. By 2023/24, the Group had already exceeded its 2024/25 target of achieving a 21.7% EBITDA margin. Consistent with strategy, Servier remains confident in its ability to achieve global annual revenues of €10 billion by 2030 and an EBITDA margin of at least 30%. Growth fueled by oncology performance in the United States The 2024/25 financial year was highlighted by several advances in oncology and partnership agreements signed, reflecting the Group's dedication to developing new therapeutic solutions for patients with rare cancers. In line with the Group's strategy, oncology continues to grow and now accounts for 32.2% of Group revenue, compared with 24.2% in 2023/24. Oncology revenues amounted to €2.21 billion in 2024-25, an increase of 54.6%. This growth stems from a significant increase in oncology sales volume following the launch of Voranigo® in the United States. Medicine sales in cardiometabolism and venous diseases underscore the Group's historic, ongoing commitment in this area. As a result, sales rose by 1.8% to €2.968 billion, boosted by strong sales performance for Daflon® in venous diseases. European Union revenues account for 40.5% of Group revenue and show a 9.2% increase over the previous financial year. The US subsidiary remained the Group's leading operating unit, with revenues of €1.496 billion in 2024/25, compared with €879 million in 2023/24, reflecting growth of 70.3%. The US market generated 21.8% of Group revenue. Pascal Lemaire, Executive Vice President Finance at Servier, said: "The Group's 2024/25 financial year results mirror our successful international growth, particularly our oncology business in the United States. They reward the risks taken as part of our targeted strategy and our policy of investing in R&D in rare diseases in oncology and in neurology where there are unmet patient needs. Our results are also a testament to Servier's decision to raise its growth targets for 2030, particularly to reach €10 billion in revenue." Targeted, collaborative R&D to enhance and strengthen the pipeline In 2024/25, the innovation strategy focused on renewing and sustaining our research and development pipeline through both internal and external growth. Incorporating AI (artificial intelligence) and data throughout the medicine development chain has now become part of Servier's ambition to improve R&D productivity to serve patients. AI helps researchers navigate biological complexity and speed up the development of treatments for the right patient at the right time, particularly in rare diseases in oncology and neurology. Targeted innovation driving growth in oncology The 2024/25 financial year was once again noteworthy for several marketing authorizations in oncology around the world, bolstering the Group's ability to develop new therapeutic solutions for rare forms of cancer with unmet medical needs, and get them to patients. Following approvals in the United States, Australia, Japan, and Brazil, Voranigo® has now been approved in Europe, bringing the total number of countries to nearly 45. Used to treat patients with a rare form of brain cancer, Voranigo® is currently administered to more than 5,500 patients in the United States and around the world through early access programs. Alongside this, Tibsovo®, a targeted therapy in hematology, has been approved for marketing in Japan. In addition, the Group has finalized three significant partnership agreements that demonstrate its focus on advancing targeted oncology therapies and the value creation potential of its R&D. The Group entered into a licensing agreement with Black Diamond Therapeutics to develop and commercialize a targeted therapy for solid tumors, including non-small cell lung cancer. Additionally, the acquisition of a precision therapy from Chinese biopharmaceutical company BioNova Pharmaceuticals Ltd also enabled the Group build on its leadership in acute leukemia. And finally, Servier joined forces with IDEAYA Biosciences to make Darovasertib available to patients. This is a potential treatment for uveal melanoma, which is a rare type of eye cancer. Featuring in the Top 10 of the PatientView Survey[3] and obtaining the leading position in the oncology category are recognition of the Group's unwavering dedication to patients and patient advocacy groups. Aspiring to be a leading force in neurology Building on its ongoing transformation, the Group aims to establish a leading neurology franchise by developing a robust pipeline in rare neurological diseases modeled on its oncology strategy. Servier is targeting three main types of neurological diseases associated with a genetic and/or immuno-inflammatory mechanism: refractory epilepsy, rare movement disorders, and neuromuscular diseases. Servier R&D is focused on small molecules that target messenger RNA, particularly antisense oligonucleotides (ASOs), as well as pharmacological molecules and monoclonal antibodies. To date, the neurology pipeline comprises eight research projects and three projects in development. Servier has initiated a Phase 1 clinical trial for a product to treat developmental and epileptic encephalopathy (DEE) in children, a rare form of epilepsy that is resistant to conventional anticonvulsant drugs. In the field of DEE, the Group has also partnered with University College London to test ASOs from Servier in innovative cell models, called brain assembloids, which replicate key aspects of human brain development and function. Leveraging the strength of its global resources, Servier also intends to become a partner of choice for innovative biotech companies in the development of new drugs that slow or halt the progression of rare neurological disorders and significantly improve patient quality of life. Over the past year, the Group has therefore enriched its pipeline with the acquisition of a first asset in autism spectrum disorder (ASD) from biotech company Kaerus Bioscience Ltd. This asset is a potential treatment for Fragile X syndrome, the most common genetic cause of ASD, for which there are currently no treatment options. Innovation continues with a focus on improving patient adherence to cardio-metabolic therapies Servier maintains its position as the world's leading pharmaceutical company in hypertension[4]. Cardiometabolism and venous diseases accounted for 43.3% of consolidated revenues in FY 2024/25, with performance driven by sales of Daflon® as well as growth in Single Pill Combinations (SPCs), which make it possible for patients with multiple and chronic conditions to take their various treatments in a single pill. Several marketing authorization applications were submitted in many countries for an extended-release triple therapy in hypertension and its first quadruple therapy. These innovations are designed to address the issue of treatment non-adherence, a major health challenge for the nearly 50% of patients with chronic diseases who do not follow their prescribed treatment plans exactly[5], which also places a financial burden on health care systems. Among other initiatives, Servier partnered with 14 institutions to sponsor the first World Adherence Day. Claude Bertrand, Executive Vice President Research and Development at Servier: "Our differentiated approach is paying off. Following major oncology launches in 2025 that consolidate our expertise in rare cancers, we are investing in rare neurological diseases while continuing our innovations in Single Pill Combinations (SPCs) in cardiometabolism. All our R&D projects are clinically grounded and focused on critical unmet medical needs, leveraging recent scientific and technological inflection points. They represent decisive and sustainable choices with one ultimate beneficiary: the patient." Last but not least, the creation of Servier's venture capital fund — Servier Ventures — will also help further the Group's R&D strategy by strengthening direct, early access to innovation in its target therapeutic areas and fueling the long-term pipeline. Through investment and support for innovative start-ups, this fund gives Servier the opportunity to position itself as a partner of choice within the biotech ecosystem, promoting the development of new and innovative medicines. Press Contact [email protected] About Servier  Servier is an independent international pharmaceutical group governed by a foundation. With its governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. The Group intends to offer targeted therapeutic solutions, particularly in rare cancers and neurological diseases, and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. More information on the Group website: servier.com Follow us on social media: LinkedIn, Facebook, X, Instagram [1] The Group's 2024/25 financial information is presented on a pro forma basis, comparable to the previous financial year, and includes Biogaran business. Excluded are restatements related to IFRS 5 regarding businesses held for sale. [2] EBITDA is used as an indicator of operating performance (EBITDA: Earnings before interest, taxes, depreciation, and amortization) based on recurring operating income excluding items such as asset disposals and other non-recurring costs. [3] PatientView's Corporate Reputation of Pharma, 2024. The Patient Perspective — Global Edition. [4] IQVIA, Analytics Link / World 84 countries – MAT Q3-2025 [5] Adherence to Long-Term Therapies: Evidence for action. World Health Organization, 2003. Logo - SOURCE Servier 21% more press release views with Request a Demo

Drug ApprovalLicense out/inPhase 1Acquisition

22 Dec 2025

·www.einpresswire.com

Breakthrough blood cancer research from UChicago Medicine presented at ASH 2025

UChicago Medicine researchers made a strong impact at the 67th American Society of Hematology (ASH) Annual Meeting, held December 6–9, 2025, in Orlando, Florida. Highlights included innovative early-line applications of CAR T-cell therapy in multiple myeloma, cutting-edge investigations in acute leukemias, outcomes-focused studies in lymphoid and myeloid malignancies, and real-world data on the use of monoclonal antibodies. Faculty and trainees from UChicago Medicine joined international colleagues to share the latest updates from transformative research in blood cancers. Reflecting the breadth and depth of hematology research, the presentations covered novel therapeutic strategies, health services research and translational science. ASH 2025 awards and trainee recognition Three UChicago Medicine trainees were recognized with Abstract Achievement Awards for their contributions spanning survivorship, immunotherapy monitoring and supportive care. Samuel Yates, MD, MS , a two-time Abstract Achievement Award recipient, presented data from the NEOMA trial, an ongoing study testing structured nutrition and exercise during acute lymphoid leukemia (ALL) treatment to optimize muscle and fat composition in adolescent young adult (AYA) patients. He also shared results from another study demonstrating how comprehensive geriatric assessment can help predict treatment and survival outcomes in older adults with acute myeloid leukemia (AML). Abigail Sneider, MD, presented data from a clinical study exploring whether next-generation sequencing of bone marrow following B-cell maturation antigen -directed CAR T-cell therapy could characterize B-cell reconstitution and serve as a complementary diagnostic marker alongside minimal residual disease (MRD) testing in multiple myeloma. Habib El-Khoury, MD, shared findings on treatment-related clonal hematopoiesis in AYA survivors of ALL, highlighting the need to further study the long-term impact of small clonal population on therapy-associated complications. Nada Aboelella, PhD, a postdoctoral fellow in the laboratory of James LaBelle, MD, PhD , Professor of Pediatrics and Director of the Pediatric Stem Cell and Cellular Therapy Program at UChicago Medicine, received both the UChicago Biological Sciences Division Career Advancement for Postdocs Travel Award and the UChicago Medicine Comprehensive Cancer Center Trainee Associate Member Travel Award, to support her attendance at the ASH conference. In an oral presentation, she shared research demonstrating that adding venetoclax, a drug that targets BCL-2, during the CAR T-cell manufacturing process can enhance therapy effectiveness by improving the quality and potency of the final CAR T-cell product. Faculty presentations In a live symposium, Michael Bishop, MD , Professor of Medicine and Director of the Hematopoietic Stem Cell Transplantation Program at UChicago Medicine, joined by Luciano Jose Costa, MD, PhD, from the University of Alabama at Birmingham and Binod Dhakal, MD, MS, from the Medical College of Wisconsin, delivered in-depth analyses on the real-world clinical complications of CAR T-cell therapy in multiple myeloma (MM). Bishop emphasized the feasibility of administering CAR T-cell therapy in an outpatient setting and highlighted the importance of multidisciplinary collaboration to ensure successful outcomes. Megan McNerny, MD, PhD , Associate Professor of Pathology, chaired the session, “ Dissecting enhancer function in hematopoietic development and disease ,” which focused on how cutting-edge approaches like 3D functional genomics, genetic manipulations and computational biology are deepening our understanding of gene regulation in both normal and disease states. Austin Wesevich, MD, MPH, MS , Instructor of Medicine, presented compelling research showing that patients with sickle cell disease (SCD) were more likely to receive negative descriptors in their medical records, such as being labeled as “noncompliant” or “refusing care.” These stigmatizing labels were associated with fewer visits from care providers, longer hospital stays, and a higher likelihood of patients leaving the hospital without any medical advice, highlighting potential disparities in care delivery. In another presentation, he shows that patients with SCD were more likely to be labeled as having “refused” medications, despite physicians being less likely to adjust treatment plans when patients declined medication. It suggests potential bias in how patient decisions are recorded and respected. In an education session, “ Treatment refinement in multiple myeloma ,” Benjamin Derman, MD , Assistant Professor of Medicine, discussed whether maintenance therapy in MM can be safely discontinued using minimal residual disease (MRD)-guided strategies. He highlighted the potential benefits, such as improved quality of life, reduced side effects and better financial management with a practical framework for treatment discontinuation. In a poster session, he shared real-world data comparing the effectiveness of anti-CD38 monoclonal antibody therapies in treatment-naïve patients versus those previously exposed, showing limited benefit with retreatment. He also presented early results from an ongoing Phase II trial indicating high response rates and manageable toxicity using a reduced-intensity quadruplet regimen – belantamab mafodotin, carfilzomib, pomalidomide and dexamethasone in MM patients who relapsed after BCMA CAR T-cell therapy. Anand Patel, MD , Assistant Professor of Medicine and Medical Director, Inpatient Leukemia Service at UChicago Medicine, presented Phase II trial data showing that a tyrosine kinase inhibitor combined with inotuzumab ozogamicin achieved deep MRD-negative remissions in newly diagnosed Philadelphia chromosome–positive ALL, with all patients reaching MRD-negative status by cycle 3 with no major safety concerns. He also shared findings from an ongoing Phase 1b trial evaluating the safety and early efficacy of a combination therapy of ivosidenib and ruxolitinib in patients with advanced IDH1-mutated myeloproliferative neoplasms. Caner Saygin, MD , Assistant Professor of Medicine at UChicago Medicine, presented interim results from an ongoing Phase I/II trial investigating the safety and efficacy of a novel combination therapy – LP-118 (a dual BCL-2/BCL-xL inhibitor), pinatinib, vincristine, and dexamethasone for adults with relapsed/refractory T-ALL/lymphoblastic lympohoma. The regimen targets pre-T-cell receptor-signaling pathways with the goal of improving survival outcomes in this difficult-to-treat population. T-cell engaging (TCE) therapies, including CAR T-cells and bispecific antibodies, have significantly transformed care for patients with B-cell non-Hodgkin lymphoma (B-NHL) because of increasing approvals and use in earlier lines of therapy. In an education session, Sonali Smith, MD , Elwood V. Jensen Professors of Medicine and Chief of the Section of Hematology/Oncology, addressed ongoing challenges with these therapies, such as toxicity, logistical complexity and accessibility. She discussed MRD-based strategies for patient selection and the integration of emerging platforms like CAR-NK and TCR-T cells to expand therapeutic potential. Finally, in a special scientific symposium, Jeffrey Rathmell, PhD , Virginia and D. K. Ludwig Chair and Professor for Cancer Research in University of Chicago's Ben May Department of Cancer Research, discussed how metabolic pathways regulate immune cell function. It focused on mitochondria responses to chronic inflammation and cellular stress – key factors shaping immune system behavior. With thousands of abstracts, live sessions and collaborative learning opportunities, ASH 2025 once again affirmed its role as the world’s leading hematology conference. UChicago Medicine’s robust presence showcased its commitment to advancing the science and clinical care of hematologic diseases through excellence in research, education and innovation. The next ASH Annual Meeting and Exposition will be held December 12–15, 2026, in New Orleans. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultCell TherapyASHPhase 2Immunotherapy

10 Dec 2025

·pharma.economictimes.indiatimes.com

Servier gets CDSCO nod for brain cancer drug Voranigo

Mumbai: French drugmaker Servier , has secured CDSCO nod for marketing its brain cancer therapy Voranigo ( Vorasidenib ) in India. Voranigo is approved for treating Grade 2 IDH-mutant astrocytoma and oligodendroglioma–types of brain cancer. Notably, the oral small-molecule which delays tumour progression is the first and only FDA-approved targeted therapy over the two indications in the world. According to the company unlike conventional chemotherapy or radiotherapy, which affects both healthy and cancerous cells, Vorasidenib is a targeted therapy that inhibits the mutant IDH enzyme responsible for tumor growth and spread. Grade 2 gliomas are a rare indication and are classified as an unmet medical need across multiple countries. Servier is placing a strong focus on India and earlier this year, the French drugmaker launched Tibsovo, another targeted therapy for IDH1-mutated acute myeloid leukemia (blood cancer) and cholangiocarcinoma. “Vorasidenib, marks a significant breakthrough directly addressing a critical unmet need in rare neuro-oncology and is a key part of Servier’s global journey in advancing cancer care,” said Aurelien Breton, Managing Director, Servier India . By Online Bureau ,

Drug Approval

100 Deals associated with Ivosidenib

External Link

KEGG	Wiki	ATC	Drug Bank
D11090	Ivosidenib	L01XX62	DB14568

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Myelodysplastic Syndromes	United States	Servier Pharmaceuticals LLC	24 Oct 2023
IDH1 Mutation Cholangiocarcinoma	Australia	Servier Laboratories (Australia) Pty Ltd.	06 Apr 2023
IDH1 Mutation Acute Myeloid Leukemia	China	Cornerstone Pharmaceutical Co., Ltd	30 Jan 2022
IDH1 Mutation Acute Myeloid Leukemia	China	Servier Pharmaceuticals LLC	30 Jan 2022
Bile Duct Neoplasms	United States	Servier Pharmaceuticals LLC	25 Aug 2021
Acute Myeloid Leukemia	United States	Servier Pharmaceuticals LLC	20 Jul 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chondrosarcoma	Phase 3	United States	Servier Bio-Innovation LLC	09 Jul 2024
Chondrosarcoma	Phase 3	United States	Institut de Recherches Intern Servier	09 Jul 2024
Chondrosarcoma	Phase 3	China	Servier Bio-Innovation LLC	09 Jul 2024
Chondrosarcoma	Phase 3	China	Institut de Recherches Intern Servier	09 Jul 2024
Chondrosarcoma	Phase 3	Japan	Servier Bio-Innovation LLC	09 Jul 2024
Chondrosarcoma	Phase 3	Japan	Institut de Recherches Intern Servier	09 Jul 2024
Chondrosarcoma	Phase 3	Australia	Servier Bio-Innovation LLC	09 Jul 2024
Chondrosarcoma	Phase 3	Australia	Institut de Recherches Intern Servier	09 Jul 2024
Chondrosarcoma	Phase 3	Belgium	Servier Bio-Innovation LLC	09 Jul 2024
Chondrosarcoma	Phase 3	Belgium	Institut de Recherches Intern Servier	09 Jul 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06501625 (ASCO_GI2026)	Phase 1/2	IDH1 Mutation Cholangiocarcinoma First line IDH1 Mutation	7	Ivosidenib 500 mg + Durvalumab + Gemcitabine/Cisplatin	pfsbntgzkl(nwskmwolhb) = cuwmsrjyjz xtmyecwxtl (jhdannfack ) View more	Positive	08 Jan 2026
NCT06081829 (ClarIDHy, CTgov)	Phase 2	Metastatic Cholangiocarcinoma	12	Ivosidenib	srzwuxrwri = vhefsczrbp fnfgeiwspc (kbukppgrxs, pdkvoqmyzl - pqjmvtogpp) View more	-	09 Dec 2025
NCT02632708 (ASH2025)	Phase 1	IDH1 Mutation Acute Myeloid Leukemia First line isocitrate dehydrogenase (IDH)1 mutation	60	Ivosidenib + intensive chemotherapy	bbabsueace(nxnxuslmke) = xhugcnfjdq iflamcjygp (nkypcwrtsr ) View more	Positive	06 Dec 2025
NCT05030441 (ASH2025)	Phase 2	IDH1 Mutation Acute Myeloid Leukemia IDH1/2-mutant	20	Ivosidenib (CCUS)	odxpwpgtpz(geenmldksk) = ohlnjeepnc qmdjoeefzl (acyxbyfcrq ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Acute Myeloid Leukemia	387	Ivosidenib monotherapy (FL IDH1-mut AML)	nzeikovvrc(npybozrimd) = bkwmpwknbm iethgeawek (yhinkaowxh, 46.0 - 84.6) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Acute Myeloid Leukemia	387	Ivosidenib+azacitidine (FL IDH1-mut AML)	nzeikovvrc(npybozrimd) = wvcwfcmfsy iethgeawek (yhinkaowxh, 21.1 - 53.1) View more	Positive	06 Dec 2025
NCT03173248 (AGILE, ASH2025)	Phase 3	IDH1 Mutation Acute Myeloid Leukemia mutant isocitrate dehydrogenase 1 (mIDH1)	146	Ivosidenib+AZA	wfwcuadtml(smzwhhwxti) = sgachfqjqi acmhtnuqtb (nrluxnvymn ) View more	Positive	06 Dec 2025
NCT03173248 (AGILE, ASH2025)	Phase 3		146	Placebo+AZA	wfwcuadtml(smzwhhwxti) = ijkvsbzfrv acmhtnuqtb (nrluxnvymn ) View more	Positive	06 Dec 2025
NCT05907057 (ALIDHE, ASH2025)	Phase 3	IDH1 Mutation Acute Myeloid Leukemia mutant isocitrate dehydrogenase 1 (mIDH1)	92	Ivosidenib+Azacitidine	odpeqqtovz(jdrwxqkjyb) = fqojwvgkgy abodvviwes (zschhvyvwp ) View more	Positive	06 Dec 2025
ASH2025	Phase 2	CCUS Clonal Cytopenia of Undetermined Significance IDH1 mutation	20	Ivosidenib	kivxjislfe(jefsgyjinb) = vpuciaofgc blowhhlfpy (fbdufgqxfd ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Acute Myeloid Leukemia	23	Ivosidenib + Azacitidine	mjuvmnqpil(lybkewzcaz) = wqtzwhdvrx dzscphjxkh (zvesfefalx ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Acute Myeloid Leukemia	23	Venetoclax + Azacitidine	xeglhbackn(dtvlkqoziy) = vvefgdgsqo pbbinziaws (nhltnrcndt ) View more	Positive	06 Dec 2025
NCT05876754 (ProvIDHe, ESMO_ASIA2025)	Phase 3	IDH1 Mutation Cholangiocarcinoma IDH1 Mutation	44	Ivosidenib 500 mg	efdbfocymv(nrdtwwcqww) = not reached zofseoxhjh (depdusezmk ) View more	Positive	05 Dec 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis